RxDoctor Payments Data

Kimberly Drake, NP

Adult Health · Marrero, LANPI 1174580245

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.4% of the total across 246 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,417, 4.7 times the $301 reported in 2021.

$3,853in general payments, 2019–2025

Across 246 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$655
  • Takeda Pharmaceuticals U.S.A., Inc.$482
  • Ardelyx, Inc.$478
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$418
  • Johnson & Johnson$385
  • Abbott$151
  • plus $1K from 27 others

What the payments were for

  • Food & beverage$3,75397%
  • Education$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,853 in reported general payments places this provider in the 75th percentile of 203 adult health providers in Louisiana.

See all adult health providers in Louisiana

Medicare billing

Part B allowed, 2024
$19,259
Medicare patients
163
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide65$43,738
Pantoprazole Sodium302$2,302
Omeprazole111$2,229
Sucralfate24$1,825
Colestipol Hcl18$1,315
Esomeprazole Magnesium27$984
Ondansetron OdtOndansetron60$865
Dicyclomine Hcl66$847
Cholestyramine LightCholestyramine12$639
Hydrocortisone23$609
Famotidine52$506
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine21$331
Ciprofloxacin Hcl19$151
Metoclopramide Hcl25$147
Baclofen11$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$655$43,73865 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 203 adult health providers in Louisiana.

Other adult health in Marrero

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →